Research progress of clinical effects of anti-Ro52/TRIM21 antibody in connective tissue diseases
Anti-Ro52 autoantibody, also known as anti-TRIM21 autoantibody, is one of the widespread autoantibodies in connective tissue diseases(CTD). It was first detected in the patients of Sjögren's syndrome(SS), which had long been considered as an unknown component of anti-SS/Ro autoantibodies. With...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College.
2021-09-01
|
| Series: | Jichu yixue yu linchuang |
| Subjects: | |
| Online Access: | http://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/a200408.pdf |
| Summary: | Anti-Ro52 autoantibody, also known as anti-TRIM21 autoantibody, is one of the widespread autoantibodies in connective tissue diseases(CTD). It was first detected in the patients of Sjögren's syndrome(SS), which had long been considered as an unknown component of anti-SS/Ro autoantibodies. With the development of molecular biology technology, antibodies against Ro52 are considered as independent auto-antibodies. However, there is still some uncertainty about the clinical applications. Recent studies have found that various connective tissue diseases can be positive for anti-Ro52 antibodies alone or in combination with other ones, leading to clinical manifestations or prognosis heterogeneity. |
|---|---|
| ISSN: | 1001-6325 |